Novartis AG Form 6-K Summary: Third Quarter 2004 Results
Business Context and Reporting Period
This Form 6-K, dated October 22, 2004, incorporates Novartis AG's third-quarter 2004 results release. The report covers the nine-month period ended September 30, 2004, and the third quarter specifically. Novartis operates globally in Pharmaceuticals and Consumer Health, headquartered in Basel, Switzerland.
Key Financial Metrics
| Metric | Nine Months 2004 (USD m) | Nine Months 2003 (USD m) | % Change |
|---|---|---|---|
| Total Sales | 20,669 | 18,134 | 14% |
| Pharmaceutical Sales | 13,528 | 11,641 | 16% |
| Consumer Health Sales | 7,141 | 6,493 | 10% |
| Operating Income | 5,005 | 4,283 | 17% |
| Operating Margin | 24.2% | 23.6% | +0.6 pts |
| Net Income | 4,389 | 3,656 | 20% |
| Basic EPS | $1.79 | $1.48 | 21% |
| Cash Flow from Operations | 4,964 | 4,767 | 4% |
| Free Cash Flow | 2,058 | 2,184 | -6% |
Balance Sheet & Liquidity: Total equity stood at USD 31.0 billion as of September 30, 2004. The debt-to-equity ratio improved to 0.18:1. Net liquidity was USD 6.65 billion. The company maintained a Triple-A credit rating from Standard & Poor's and Moody's.
Material Changes vs. Prior Period
- Sales Growth Drivers: The 14% sales increase was driven by volumes (+7 percentage points), currency benefits (+5 percentage points), acquisitions (+1 percentage point), and price increases (+1 percentage point). Local currency (lc) growth was 9%.
- Pharmaceuticals: Achieved double-digit growth (+16% USD, +11% lc) with market share gains. Key drivers included the cardiovascular franchise (Diovan, Lotrel) and oncology (Gleevec, Zometa, Femara).
- Consumer Health: Sales rose 10% (+5% lc). Strong growth in OTC and Medical Nutrition (boosted by the Mead Johnson acquisition) offset slower growth in the Sandoz generics business.
- Profitability: Operating income grew faster than sales (17% vs 14%), expanding margins by 0.6 percentage points due to improved Cost of Goods Sold (COGS) and controlled Marketing & Sales expenses.
- Impairments & Charges: Other income/expenses included a USD 73 million goodwill impairment in Sandoz and a USD 18 million inventory write-down in Animal Health.
Guidance, Outlook, and Risks
- Full Year Outlook: Management expects high-single-digit sales growth for the full year 2004. Pharmaceuticals are projected to deliver high-single-digit to low-double-digit sales growth in local currencies. Operating and net income are predicted to be markedly higher than 2003.
- Q4 Expectations: Operating expenses are expected to be significantly higher in Q4 compared to Q4 2003, particularly in Marketing & Sales and R&D, due to major phase III clinical trials.
- Share Repurchases: Novartis completed its third share repurchase program (22.8 million shares for USD 1 billion) and initiated a fourth. Total repurchases in 2004 reached 36.4 million shares for USD 1.7 billion.
- Risks: Forward-looking statements are subject to risks including regulatory delays, clinical trial results, patent protection, pricing pressures, and competition. Additional impairments in the generics market cannot be excluded.
Investor Verification Checklist
- Sandoz Performance: Verify the sustainability of the Sandoz generics business given the reported goodwill impairment and competitive pricing pressures.
- Acquisition Integration: Assess the contribution of the Mead Johnson acquisition to Medical Nutrition sales and the integration of Durascan and Sabex in Sandoz.
- Q4 Expense Run Rate: Confirm the impact of anticipated higher Q4 R&D and Marketing expenses on full-year margins.
- Regulatory Milestones: Monitor FDA and EU approval timelines for key pipeline products (e.g., Femara extended adjuvant indication, Xolair, Prexige).
- Chiron Investment: Review the status of the Chiron investment, which contributed significantly less income in 2004 due to flu vaccine production issues.